Possibilities for the pharmacological exploitation of ischaemic preconditioning.
Parratt
J R
JR
Department of Physiology and Pharmacology, University of Strathclyde, Glasgow, UK.
D000818:Animals; D003327:Coronary Disease / Q000378:metabolism; D004285:Dogs; D004789:Enzyme Activation; D019204:GTP-Binding Proteins / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D006801:Humans; D051379:Mice; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D009569:Nitric Oxide / Q000494:pharmacology; D009712:Nucleotides, Cyclic / Q000378:metabolism; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D058915:Purinergic P1 Receptor Antagonists; D015398:Signal Transduction
D009712:Nucleotides, Cyclic; D058915:Purinergic P1 Receptor Antagonists; D009569:Nitric Oxide; D011493:Protein Kinase C; D010727:Phosphoric Diester Hydrolases; D019204:GTP-Binding Proteins